EXCLUSIVE: Kourtney Kardashian Barker's Lemme Is the Latest Brand Aiming to Make Fiber Cool
Today, Kardashian Barker's supplement brand Lemme is launching its Lemme No. 2 for $30, a daily fiber and probiotic strawberry-flavored gummy to boost regularity, support overall gut health and fill nutrient gaps. Lemme No. 2 is the brand's latest addition to its gut health offering, which includes bestsellers like Lemme Debloat, $30. To start, it will be available exclusively on lemmelive.com.
More from WWD
EXCLUSIVE: Assouline and Technogym Team on 'The Art of Wellness' Coffee-table Book
Tate McRae Gets 'Pierced' in Grace Ling Set for 'Tonight Show Starring Jimmy Fallon' Performance
Amanda Seyfried Puts Sparkling Spin on Suiting for 'Tonight Show Starring Jimmy Fallon,' Talks Sabrina Carpenter in 'Mamma Mia! 3'
According to the National Institute of Health, only 5 percent of people reach the daily suggested amount of fiber — about 25 grams for women and 38 grams for men, ages 19 to 50. Insufficient fiber can cause constipation, bloating and gas, as well as have longer-term effects such as high cholesterol.
'Research tells us most of the general population is fiber deficient with wide-reaching implications. That's why Lemme No. 2 is formulated with 4 grams of non-GMO prebiotic fiber per serving, plus 2 clinically studied probiotics — scientifically shown to support regularity, digestive health and good gut bacteria,' said Leona West-Fox, functional nutritionist and Lemme medical advisory board member.
Lemme cofounder Simon Huck added: 'When we think about fiber, we immediately go to regularity, but there are so many other things in your body, like metabolic function, overall digestion, bloating [and] hormone balance. Everything in your body is rooted from fiber.'
The formula includes vitamin D, another nutrient that many are deficient in, which can boost immunity, support bone health and promote a healthy gut microbiome.
Over the past couple of years, more brands have been jumping into the fiber game to meet this growing consumer need and refresh the category. According to Nielsen IQ, fiber supplements overall exceeded $188 million in omnichannel sales in a year, having grown 25 percent from the previous period — the most popular format within the category sales- and units-wise is gummies. Lemme is the latest brand to bet on the growing market.
'Fiber is the moment,' said Lemme cofounder Simon Huck. 'It's a category that we have been so interested in for the last two years. It's, again, one of those products that is constantly requested from us.'
The product has been in development for a year-and-a-half, according to Huck, who noted the process was quite long given they formulated without sugar.
This launch follows Lemme's latest retail expansion into iHerb, which has allowed the brand to expand its reach.
'Part of the challenge was, we want to launch in all sorts of different places, but it takes a lot of resources,' Huck said. '[iHerb] ships to almost every single country in the world.'
Within two days of launching on the platform, 60 percent of Lemme's products were already sold out, according to Huck. As far as what's next, Lemme has a full pipeline of products in 2025, including a launch into a brand new category.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
US pediatric group breaks with federal policy, recommends COVID-19 vaccines for young children
(Reuters) -The American Academy of Pediatrics on Tuesday recommended that all young children get vaccinated against COVID-19, differing from federal policy that no longer recommends routine COVID vaccination for healthy children. The U.S. pediatric group, in its latest policy document, said all young children aged 6-23 months should receive a COVID-19 vaccine regardless of previous doses or SARS-CoV-2 infection, and recommended vaccination for older children in certain risk groups. The U.S. Centers for Disease Control and Prevention said in May COVID-19 vaccines are now an option for healthy children when parents and doctors agree that it is needed. Prior to the new guidance, the agency routinely recommended updated COVID vaccines for everyone aged six months and older, in line with the advice of its panel of outside experts. "Shared clinical decision-making (involving parents and doctors) can be difficult to implement because it lacks clear guidance and does not emphasize the importance of vaccinating people at high risk of severe disease," the AAP said in a statement. In early July, the AAP and other major medical groups sued Health and Human Services Secretary Robert F. Kennedy Jr. for unilaterally removing routine vaccination recommendations. The rate of COVID-19 hospitalization for children under 2 years is the highest among pediatric age groups, and for children aged 6-23 months, it is comparable to people aged 50-64 years, the group said on Tuesday, citing CDC data. The U.S. Department of Health and Human Services earlier this month said it is reinstating a federal task force for safer childhood vaccines after a 27-year hiatus.
Business Insider
a day ago
- Business Insider
Pfizer Canada, BioNTech get Health Canada approval for COVID variant vaccine
Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older. The updated COMIRNATY vaccine targets the Omicron LP.8.1 variant, one of the most recently circulating SARS-CoV-2 lineages. This season's Pfizer and BioNTech COVID-19 vaccine will be available in pharmacies across the country in the fall. The public program operates according to the eligibility criteria determined by each province. If an individual meets these criteria, they will be eligible to receive the vaccine for free. Efforts are ongoing in collaboration with private insurers and payers to streamline reimbursement processes within the private sector, for those who do not meet public program requirements. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
a day ago
- Business Insider
Invivyd says PEMGARDA effective against XFG variant of SARS-CoV-2
Invivyd (IVVD) announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA against the currently dominant and growing XFG variant of SARS-CoV-2. Notably, and consistent with all dominant variants for the past three years, XFG did not generate any meaningful change to the in vitro neutralization activity of pemivibart or VYD2311, the company's next generation COVID-19 monoclonal antibody candidate, as the epitopes targeted by pemivibart and VYD2311 remain structurally intact. PEMGARDA is authorized by the U.S. FDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients. Currently, the level of COVID-19 viral activity detected in wastewater in 12 states is reported as high or very high levels as of early August, and the U.S. Centers for Disease Control and Prevention estimates that COVID-19 infections are growing or likely growing in 34 states and declining in zero states, according to forecasting models. Further, the company estimates that every clinical variant reported in the CDC COVID Data Tracker since the Omicron BA.2 lineage has been susceptible to pemivibart, even if untested, due to the consistent structural integrity of the epitope targeted by pemivibart. Therefore, Invivyd anticipates continued meaningful clinical activity for pemivibart for the foreseeable future if the epitope pemivibart targets remains intact. Elevate Your Investing Strategy:
